title: [Innsbruck results of bone marrow transplantation in treatment of hematologic neoplasms and solid tumors].
abstract: 87 patients underwent bone marrow transplantation (BMT) in Innsbruck between 1983 and 1992. 81 patients were suffering from hematologic malignancies and severe aplastic anemia and six patients had advanced solid tumours/sarcoma. 56% of the patients undergoing HLA-identical sibling BMT were in an advanced or refractory stage of disease at the time of BMT. 19 patients underwent autologous BMT and 5 patients received a graft from an HLA-matched unrelated donor. Patients were treated with standard conditioning regimens according to the underlying disease. Cyclosporine A (CsA) was given prophylactically against graft-versus-host disease (GVHD) either alone or in combination with methotrexate. Probability of survival for patients transplanted in the first chronic phase of chronic myelogenous leukemia (CML) was 85%, whereas the disease free survival (DFS) for patients transplanted in accelerated phase or blast crisis was only 40%. DFS for acute myelogenous leukemia (AML) in first complete remission and acute lymphoblastic leukemia (ALL) standard-risk (i.e., first or second complete remission) was 71% and 60%, respectively. All patients transplanted for non-Hodgkin's lymphoma (NHL) or Hodgkin's disease had refractory or advanced disease. Probability of survival for lymphoma patients was 60%. Acute GVHD > grade II developed in 35% of patients undergoing HLA-identical sibling BMT (46% in the high-risk group vs. 21% in the standard-risk group). Main causes of death in the high-risk group were relapse (31%), severe bacterial or fungal infections (17%), interstitial pneumonia (11%) and acute GVHD (6%).
authors.affiliation: Abteilung für Klinische Immunbiologie und Knochenmarktransplantation, Universitätsklinik für Innere Medizin, Innsbruck.
authors.forename: D
authors.initials: D
authors.lastname: Nachbaur
authors.forename: H
authors.initials: H
authors.lastname: Schwaighofer
authors.forename: J
authors.initials: J
authors.lastname: Thaler
authors.forename: W
authors.initials: W
authors.lastname: Weyrer
authors.forename: M
authors.initials: M
authors.lastname: Fink
authors.forename: W
authors.initials: W
authors.lastname: Nussbaumer
authors.forename: E
authors.initials: E
authors.lastname: Fritsch
authors.forename: D
authors.initials: D
authors.lastname: Niederwieser
mesh_terms: D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000209:etiology / Q000401:mortality / Q000517:prevention & control; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007938:Leukemia / Q000401:mortality / Q000628:therapy*; D008223:Lymphoma / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous
vernacular_title: Innsbrucker Ergebnisse mit der Knochenmarktransplantation in der Behandlung hämatologischer Neoplasien und solider Tumoren.